After investors got through the shock that Human Genome Sciences'
That's not happening quite yet.
|Benlysta Net Sales (in millions)||$7.8||$18.8||$25.7|
Source: Company releases. N/A = not applicable.
HGS broke down the sales by month, but I'm not sure what to do with the data. During the quarter, gross sales went from about $9.2 million in the first four weeks to $8.4 million to $10 million. There's improvement from the first to the third period, but the middle month shows there's still variation in the sales. Was the $10 million a trend up, or just some of that variation?
Working in HGS and marketing partner GlaxoSmithKline's
Blaming lackluster sales on holidays sounds like an excuse, but it's a necessary evil of doing quarter-over-quarter comparisons. The quarter-over-quarter growth of Dendreon's
On the other hand, there's Regeneron Pharmaceuticals
I'm not sure investors should give up on HGS just yet. Accelerated growth tends to come on without warning. But investors should keep the company on a short leash.
Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Dendreon. Motley Fool newsletter services have recommended buying shares of GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.